Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and purvalanol a

lestaurtinib has been researched along with purvalanol a in 1 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(purvalanol a)		Trials
(purvalanol a)		Recent Studies (post-2010) (purvalanol a)
124126386042

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)purvalanol a (IC50)
Cyclin-T1Homo sapiens (human)0.0497
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.0193
Serine/threonine-protein kinase PAK 4Homo sapiens (human)0.13
G1/S-specific cyclin-E2Homo sapiens (human)0.035
Cyclin-dependent kinase 1Saccharomyces cerevisiae S288C0.08
Insulin receptorHomo sapiens (human)5
Cyclin-dependent kinase 1Homo sapiens (human)0.0968
Cyclin-dependent kinase 4Homo sapiens (human)0.6808
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.1833
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1026
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)9
Cyclin-A2Homo sapiens (human)0.0556
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)9
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)9
G1/S-specific cyclin-D1Homo sapiens (human)0.85
G1/S-specific cyclin-E1Homo sapiens (human)0.035
Cyclin-dependent kinase 2Homo sapiens (human)0.0617
Mitogen-activated protein kinase 3 Homo sapiens (human)9
Cyclin-dependent kinase 7Homo sapiens (human)0.0497
Cyclin-dependent kinase 9Homo sapiens (human)0.0497
Cyclin-HHomo sapiens (human)0.0497
Cyclin-A1Homo sapiens (human)0.05
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.0623
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)0.3
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.0623
Cdc2Patiria pectinifera0.27
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.0193

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bharate, SB; Raghuvanshi, R1

Other Studies

1 other study(ies) available for lestaurtinib and purvalanol a

ArticleYear
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022